Results 81 to 90 of about 2,193 (158)

Delamanid and pretomanid have comparable bactericidal activity but pretomanid potently inhibits Mycobacterium tuberculosis ribosomal rRNA synthesis

bioRxiv : the preprint server for biology
ABSTRACT Background The nitroimidazoles delamanid and pretomanid play an important role in contemporary tuberculosis treatment. It is unclear whether delamanid and pretomanid have meaningfully different activity since both reduce Mycobacterium tuberculosis
Matthew J. Reichlen, Emmanuel Musisi, Samuel T. Tabor, Holly Nielsen, Ashley M. Gerwing, Firat Kaya, Matthew Zimmerman, Martin I. Voskuil, Gregory T. Robertson, Nicholas D. Walter   +9 more
openaire   +3 more sources

Experiences in the introduction of bedaquiline pretomanid linezolid for drug-resistant tuberculosis in Kyrgyzstan

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
In Kyrgyzstan, drug-resistant tuberculosis poses a significant challenge. Recognizing the potential of the BPaL regimen, the World Health Organization recommended its use for selected drug-resistant TB cases under operational research conditions in 2020.This report presents experiences and results from the BPaL operational research under the LIFT-TB ...
Myrzaliev, B., Ahmatov, M., Duishekeeva, A., Kulzhabaeva, A., Kadyrov, A., Toktogonova, A., Abdulaeva, G., Wares, D.F., Mirtskhulava, V., Mbenga, M., Slyzkyi, A., Foraida, S., Diachenko, M., Juneja, S., Turdumambetova, G., Musaeva, A., Gebhard, A.   +16 more
openaire   +2 more sources

Promise and Peril of Pretomanid–Rifamycin Regimens for Drug-susceptible Tuberculosis

American Journal of Respiratory and Critical Care Medicine, 2023
Gustavo E. Velásquez, Payam Nahid
openaire   +2 more sources

Breaking barriers in extensively drug-resistant TB: pretomanid-centred long regimen achieves cure in a bedaquiline-resistant strain. [PDF]

IJTLD Open
Schiuma M, Piubello A, Saluzzo F, Cattaneo D, Salari F, Covizzi A, Rizzo A, Fama F, Ciubotariu C, Lombardi A, Antinori S, Riva A, Cirillo DM, Gori A, Torre A.   +14 more
europepmc   +1 more source

Financial Feasibility of BPaL(M) Under Pretomanid Price Scenarios - China, 2023-2024. [PDF]

China CDC Wkly
Ren J, Wang N, Zhu H, Nie W, Sun F, Xiong Y, Fu L, Luo H, Cheng S, Zhao Y, Huang F.   +10 more
europepmc   +1 more source

Pretomanid vs delamanid in a bedaquiline-linezolid regimen: efficacy in a high-burden tuberculosis mouse model. [PDF]

Antimicrob Agents Chemother
Cummings JE, Woolhiser LK, Guglielmi V, Romano A, Pauly S, Zimmerman M, Kaya F, Walter ND, Robertson GT, Slayden RA.   +9 more
europepmc   +1 more source

Outcomes and Treatment-limiting Adverse Events of Patients Receiving BPaL and BPaL-FQ in California. [PDF]

Open Forum Infect Dis
Katrak SS, Wang RC, Keh CE, Nabity SA, Okada RC, Raftery A, Wendorf KA, Agraz-Lara R, Chakrabarty M, Chevinsky JR, Chitnis AS, Dasgupta-Tsinikas S, Goozé L, Kadakia A, Kaiser C, Louie JK, Morgan J, Nguyen TD, Percak J, Polesky AH, Radner A, Sahni H, Sreenivasan M, Sherrick R, Soukup JD, Waterman C, Yeturu P, Yu S, Barry PM.   +28 more
europepmc   +1 more source

Strain diversity drives heterogeneous responses to tuberculosis combination therapy. [PDF]

Antimicrob Agents Chemother
Yoon MH, Culviner PH, Pereira Moraes M, Nitta H, Thuong NTT, Fortune SM, Aldridge BB.   +6 more
europepmc   +2 more sources

Orchestrating faster access to products of non-profit R&D: a case study of a novel regimen for drug-resistant tuberculosis. [PDF]

BMJ Glob Health
Moon S, Vieira MCF, Large K.
europepmc   +1 more source

Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? [PDF]

The Lancet Respiratory Medicine, 2019
Lindsay, McKenna, Jennifer, Furin
openaire   +2 more sources